Rajani C, Jia W
Pharmaceutical policy expert Mina Tadrous of the University of Toronto said a generic semaglutide medication is unlikely to be approved before late spring or early summer and that Canadians should not be expecting a product in January, as reported by BNN Bloomberg
Cagrilintide's strongest use is in combination CagriSema (with semaglutide) reached 20.4% in REDEFINE 1, but did not reach noninferiority versus tirzepatide 15 mg in REDEFINE 4
In contrast, Zepbound was originally approved under the name Mounjaro for type 2 diabetes in 2022, followed by Zepbound in 2023 for weight loss
You may qualify if: Individuals being treated for cancer or those with a history of major gastric surgeries (such as gastric sleeve, bypass, or banding) generally do not qualify
EDTA (ethylenediaminetetraacetic acid): Often added to salad dressings, mayonnaise, and other emulsified products